Azathioprine and Acenocoumarol Drug Interaction in Patients with Crohn's Disease: A Case Report.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY

Current drug safety Pub Date : 2023-01-01 DOI:10.2174/1574886317666220425113613

Syrine Ben-Hammamia, Ons Charfi, Anis Belhadj, Amal Bouchrika, Faouzi Chebbi, Ghozlane Lakhoua, Sihem El Aidli

{"title":"Azathioprine and Acenocoumarol Drug Interaction in Patients with Crohn's Disease: A Case Report.","authors":"Syrine Ben-Hammamia, Ons Charfi, Anis Belhadj, Amal Bouchrika, Faouzi Chebbi, Ghozlane Lakhoua, Sihem El Aidli","doi":"10.2174/1574886317666220425113613","DOIUrl":null,"url":null,"abstract":"Background: Acenocoumarol is an anticoagulant with numerous drug reactions. We report here, an unusual interaction between acenocoumarol and azathioprine.Case presentation: A 35-year-old woman, treated with acenocoumarol for thrombosis of the superior mesenteric vein, was prescribed azathioprine for Crohn's disease. Three days later, INR values decreased from 2.36 to 1.48. The dose of acenocoumarol had to almost be doubled to reach an INR value of 2.56. The interaction between azathioprine and acenocoumarol was then suspected. Few similar cases of interactions between azathioprine and another coumarin derivative, warfarin, have been reported. To our knowledge, this is the second case of such interaction reported with acenocoumarol in literature.Conclusion: Thus, despite the rarity of this interaction reporting, we draw attention to the importance of close monitoring of INR values in patients treated with acenocoumarol associated with azathioprine.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574886317666220425113613","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Acenocoumarol is an anticoagulant with numerous drug reactions. We report here, an unusual interaction between acenocoumarol and azathioprine.

Case presentation: A 35-year-old woman, treated with acenocoumarol for thrombosis of the superior mesenteric vein, was prescribed azathioprine for Crohn's disease. Three days later, INR values decreased from 2.36 to 1.48. The dose of acenocoumarol had to almost be doubled to reach an INR value of 2.56. The interaction between azathioprine and acenocoumarol was then suspected. Few similar cases of interactions between azathioprine and another coumarin derivative, warfarin, have been reported. To our knowledge, this is the second case of such interaction reported with acenocoumarol in literature.

Conclusion: Thus, despite the rarity of this interaction reporting, we draw attention to the importance of close monitoring of INR values in patients treated with acenocoumarol associated with azathioprine.

查看原文本刊更多论文

硫唑嘌呤与阿塞诺古美尔在克罗恩病患者中的相互作用:1例报告。

背景:阿塞诺古豆醇是一种抗凝血剂，具有多种药物反应。我们在这里报告，阿塞诺古豆酚和硫代嘌呤之间的不寻常的相互作用。病例介绍:一名35岁的女性，因肠系膜上静脉血栓形成而接受阿塞诺古豆醇治疗，同时处方硫唑嘌呤治疗克罗恩病。3天后，INR值从2.36下降到1.48。阿塞诺古豆素的剂量几乎要加倍才能达到2.56的INR值。然后怀疑硫唑嘌呤和阿塞诺古豆酚之间的相互作用。偶氮噻吩嘌呤与另一香豆素衍生物华法林之间的类似相互作用的病例报道很少。据我们所知，这是文献中报道的与阿塞诺古玛罗相互作用的第二例。结论:因此，尽管这种相互作用的报道很少见，我们还是要注意密切监测阿塞诺古玛罗联合硫唑嘌呤治疗患者的INR值的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.